KRAS and neoplasm: In the QUASAR trial, HER2 overexpression was observed in 17 of 811 (2.1%) KRAS/BRAF WT tumours compared with one of 421 (0.2%) tumours harbouring a KRAS or BRAF mutation (p = 0.01).